Modality
Gene Editing
MOA
EZH2i
Target
KRASG12D
Pathway
Apoptosis
GISTCLLCTCL
Development Pipeline
Preclinical
Sep 2018
→ Aug 2025
PreclinicalCurrent
NCT04581885
2,663 pts·GIST
2018-09→2025-08·Completed
2,663 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-08-287mo agoInterim· GIST
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2025-08-28 · 7mo ago
GIST
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04581885 | Preclinical | GIST | Completed | 2663 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 |